ArticleFrontiers in oncology2023

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer.

Jia-Yi Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.